Osteopontin modulates malignant pleural mesothelioma cell functions in vitro

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 2205-2214

  Ohashi, Rina ^a   Tajima, Ken ^a   Takahashi, Fumiyuki ^a   Cui, Ri ^a   Gu, Tao ^a   Shimizu, Kazue ^a   Nishio, Kazuto ^b   Fukuoka, Kazuya ^c   Nakano, Takashi ^c   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

v 3 integrin; Malignant pleural mesothelioma; Osteopontin

Indexed keywords

BETA ACTIN; FOCAL ADHESION KINASE; GLYCINE AMIDINOTRANSFERASE; MESSENGER RNA; OSTEOPONTIN; PROTEIN ANTIBODY; VITRONECTIN RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; IMMOBILIZED CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MODULATION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; INTEGRIN ALPHAVBETA3; MESOTHELIOMA; OLIGOPEPTIDES; OSTEOPONTIN; PHOSPHORYLATION; PLEURAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 67650917923     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Nakano T, Chahinian AP, Shinjo M, Togawa N, Tonomura A, Miyake M, Ninomiya K, Yamamoto T and Higashino K: Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 85: 2375-2384, 1999. (Pubitemid 29244846)
2. Ong ST and Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 14: 1007-1017, 1996. (Pubitemid 26085549)
3. Corson JM: Pathology of mesothelioma. Thorac Surg Clin 14: 447-460, 2004.
4. Denhardt DT and Guo X: Osteopontin: a protein with diverse functions. FASEB J 7: 1475-1482, 1993.
5. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM and Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95: 713-724, 1995.
6. Zheng DQ, Woodard AS, Tallini G and Languino LR: Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem 275: 24565-24574, 2000.
7. Chen Q, Kinch MS, Lin TH, Burridge K and Juliano RL: Integrin-mediated cell adhesion activates mitogen-activated protein kinases. J Biol Chem 269: 26602-26605, 1994. (Pubitemid 24332843)
8. Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, Al-Katib W, Chambers AF and Tuck AB: Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 1: 810-819, 2003.
9. Furger KA, Menon RK, Tuck AB, Bramwell VH and Chambers AF: The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 1: 621-632, 2001. (Pubitemid 33772040)
10. Bautista DS, Xuan JW, Hota C, Chambers AF and Harris JF: Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 269: 23280-23285, 1994. (Pubitemid 24283318)
11. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V and Kundu GC: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6: 819-830, 2006. (Pubitemid 44883934)
12. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87, 2006. (Pubitemid 43247403)
13. Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR and Welch DR: Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 23: 123-133, 2006. (Pubitemid 44440172)
14. Cook AC, Chambers AF, Turley EA and Tuck AB: Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy. J Biol Chem 281: 24381-24389, 2006. (Pubitemid 44274210)
15. Standal T, Borset M and Sundan A: Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26: 179-184, 2004. (Pubitemid 39424636)
16. Caers J, Gunthert U, De Raeve H, Van Valckenborgh E, Menu E, Van Riet I, Van Camp B and Vanderkerken K: The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model. Br J Haematol 132: 469-477, 2006. (Pubitemid 43381618)
17. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C and Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-1573, 2005. (Pubitemid 41434635)
18. Greillier L, Baas P, Welch JJ, Hasan B and Passioukov A: Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 12: 375-390, 2008. (Pubitemid 352790451)
19. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K and Fukuchi Y: Differential osteopontin expression in lung cancer. Cancer Lett 171: 215-222, 2001. (Pubitemid 32772809)
20. Takahashi K, Takahashi F, Hirama M, Tanabe KK and Fukuchi Y: Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity. Lung Cancer 41: 145-153, 2003. (Pubitemid 36842777)
21. Maeda K, Takahashi K, Takahashi F, Tamura N, Maeda M, Kon S, Uede T and Fukuchi Y: Distinct roles of osteopontin fragments in the development of the pulmonary involvement in sarcoidosis. Lung 179: 279-291, 2001. (Pubitemid 34442214)
22. Yokosaki Y, Matsuura N, Sasaki T, Murakami I, Schneider H, Higashiyama S, Saitoh Y, Yamakido M, Taooka Y and Sheppard D: The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem 274: 36328-36334, 1999.
23. Frey AB, Wali A, Pass H and Lonardo F: Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. Histopathology 50: 720-726, 2007. (Pubitemid 46683928)
24. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF and Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol 145: 610-623, 1994. (Pubitemid 24285968)
25. Weber GF, Ashkar S, Glimcher MJ and Cantor H: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 271: 509-512, 1996. (Pubitemid 26044470)
26. Giuffrida A, Vianale G, Di Muzio M, Pass HI, Coletti A, Birarelli P, Procopio A and Modesti A: Modulation of integrin expression on mesotheliomas: the role of different histotypes in invasiveness. Int J Oncol 15: 437-442, 1999.
27. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM: Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 63: 2079-2087, 2003. (Pubitemid 36538610)
28. Kumar CC: Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 4: 123-131, 2003.
29. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG and Huber PE: Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11: 6270-6279, 2005. (Pubitemid 41262958)
30. Mulgrew K, Kinneer K, Yao XT, Ward BK, Damschroder MM, Walsh B, Mao SY, Gao C, Kiener PA, Coats S, Kinch MS and Tice DA: Direct targeting of alpha v beta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 5: 3122-3129, 2006.
31. Cai W, Wu Y, Chen K, Cao Q, Tice DA and Chen X: In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res 66: 9673-9681, 2006.
32. Boylan AM, Sanan DA, Sheppard D and Broaddus VC: Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin alpha v beta 5. J Clin Invest 96: 1987-2001, 1995.